Clinical Trial Update: Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a selective JAK inhibitor for interstitial lung disease due to systemic disease and skin tightness in systemic sclerosis, comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Systemic Sclerosis
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• Selective JAK inhibitor

Snippet

Sponsor: Assiut University | Conditions: Interstitial Lung Disease Due to Systemic Disease (Disorder) | Phase 3 | Status: COMPLETED